Jagsonpal Pharmaceuticals Limited — Investor Meet, 03-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharma posted robust H1 FY26 results with Revenue up 10.2% YoY to ₹150.1 Cr and PAT surging 39.2% YoY to ₹23.4 Cr. Q2 FY26 revenue was stable at ₹74.5 Cr, with PAT growing 9.7% YoY to ₹12.6 Cr, despite temporary sales moderation from GST 2.0 transition. Management noted strong execution and cost control, passing GST benefits to customers. The company maintains a healthy cash balance of ₹160.4 Cr and recently appointed a new COO and CFO, indicating a confident outlook for accelerating growth.